|
Name |
Dihydroagarofuran
|
Molecular Formula | C15H26O | |
IUPAC Name* |
(2S,6R,9S)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecane
|
|
SMILES |
C[C@H]1CCC[C@]2(C13C[C@H](CC2)C(O3)(C)C)C
|
|
InChI |
InChI=1S/C15H26O/c1-11-6-5-8-14(4)9-7-12-10-15(11,14)16-13(12,2)3/h11-12H,5-10H2,1-4H3/t11-,12-,14+,15?/m0/s1
|
|
InChIKey |
HVAVUZLEYSAYGE-KFUGQBAVSA-N
|
|
Synonyms |
Dihydroagarofuran; trans-Dihydroagarofuran; Deoxybaimuxino; .beta.-Dihydroagarofuran; .beta.-dihydro-agarofuran; Dihydro-.beta.-agarofuran; .beta.-Agarofuran, dihydro-; 2H-3,9a-Methano-1-benzoxepin, octahydro-2,2,5a,9-tetramethyl-; (2S,6R,9S)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecane; (3R,5aS,9R,9aS)-2,2,5a,9-Tetramethyloctahydro-2H-3,9a-methanobenzo[b]oxepine; 2H-3,9a-Methano-1-benzoxepin, octahydro-2,2,5a,9-tetramethyl-, (3R,5aS,9R,9aS)-; 2H-3,9a-Methano-1-benzoxepin, octahydro-2,2,5a,9-tetramethyl-, [3R-(3.alpha.,5a.alpha.,9.alpha.,9a.alpha.)]-
|
|
CAS | NA | |
PubChem CID | 6427117 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 222.37 | ALogp: | 3.9 |
HBD: | 0 | HBA: | 1 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 9.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 16 | QED Weighted: | 0.575 |
Caco-2 Permeability: | -4.578 | MDCK Permeability: | 0.00001490 |
Pgp-inhibitor: | 0.232 | Pgp-substrate: | 0 |
Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.603 |
30% Bioavailability (F30%): | 0.698 |
Blood-Brain-Barrier Penetration (BBB): | 0.358 | Plasma Protein Binding (PPB): | 95.73% |
Volume Distribution (VD): | 1.814 | Fu: | 3.49% |
CYP1A2-inhibitor: | 0.113 | CYP1A2-substrate: | 0.468 |
CYP2C19-inhibitor: | 0.359 | CYP2C19-substrate: | 0.921 |
CYP2C9-inhibitor: | 0.324 | CYP2C9-substrate: | 0.453 |
CYP2D6-inhibitor: | 0.036 | CYP2D6-substrate: | 0.764 |
CYP3A4-inhibitor: | 0.302 | CYP3A4-substrate: | 0.307 |
Clearance (CL): | 9.135 | Half-life (T1/2): | 0.108 |
hERG Blockers: | 0.049 | Human Hepatotoxicity (H-HT): | 0.658 |
Drug-inuced Liver Injury (DILI): | 0.049 | AMES Toxicity: | 0.019 |
Rat Oral Acute Toxicity: | 0.039 | Maximum Recommended Daily Dose: | 0.718 |
Skin Sensitization: | 0.532 | Carcinogencity: | 0.503 |
Eye Corrosion: | 0.387 | Eye Irritation: | 0.878 |
Respiratory Toxicity: | 0.956 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003049 | 1.000 | D0V8HA | 0.288 | ||||
ENC002337 | 0.544 | D0H1QY | 0.281 | ||||
ENC002074 | 0.492 | D0U3GL | 0.280 | ||||
ENC000085 | 0.451 | D0L2LS | 0.253 | ||||
ENC005519 | 0.451 | D0Z1XD | 0.250 | ||||
ENC001322 | 0.403 | D0Q6NZ | 0.250 | ||||
ENC002262 | 0.381 | D08QKJ | 0.244 | ||||
ENC001893 | 0.381 | D0I2SD | 0.244 | ||||
ENC001172 | 0.381 | D09NNA | 0.234 | ||||
ENC000592 | 0.379 | D03XOC | 0.233 |